Roche, Merck Serono and Abbott in BioRN cluster
European drug majors Roche and Merck Serono and the USA's Abbott Laboratories are joining forces in the development of the Biotechnology Cluster Rhine-Neckar (BioRN) towards a leading position in the field of medical biotechnology in Europe. The BioRN cluster was recently awarded a 40.0 million-euro ($50.6 million) federal grant by the German Ministry for Education and Research as one of the top five high-tech clusters in that country. In addition, BioRN is the host of this year's BIO-Europe, which has established itself as the world's largest stand-alone partnering conference, according to its organizer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze